Format

Send to

Choose Destination
Microbes Infect. 2005 May;7(5-6):947-54.

Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins.

Author information

1
Department of Medicine, School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA. mhorwitz@mednet.ucla.edu

Abstract

rBCG30, the first vaccine against tuberculosis demonstrated more potent than BCG in preclinical studies, is the prototype of a class of vaccines that utilize BCG as a host organism for expressing and secreting Mycobacterium tuberculosis major extracellular proteins. The vaccine is based on the concept that extracellular proteins of intracellular pathogens are key immunoprotective molecules. rBCG30, which expresses and secretes large amounts of the M. tuberculosis 30 kDa major secretory protein, is currently in human clinical trials.

PMID:
15919223
DOI:
10.1016/j.micinf.2005.04.002
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for eScholarship, California Digital Library, University of California
Loading ...
Support Center